Loading…
Inflammatory bowel disease , a idiopathic conditions where alterations in the normal microflora have been implicated as responsible for initiation, is an area where the use of probiotics has been regarded as promising
In inflammatory bowel diseases (IBD), the therapeutic benefit and mucosal healing from specific probiotics may relate to the modulation of dendritic cells (DCs).
CD80 and CD86 were induced by most probiotic strains in ulcerative colitis (UC) patients whereas only B. bifidum induced CD80 and CD86 expression in Crohn’s disease (CD) patients.
Interleukin-10 (IL-10) and transforming growth factor beta (TGF-beta) production was increased in a dose-independent manner while TLR expression was decreased by all Probiotics (living agents) except B. bifidum in DCs from UC patients.
Probiotic bacteria favorably modulate the expression of co-stimulatory molecules, pro-inflammatory cytokines and TLRs in DCs from IBD patients.
It should be noted that many of the publications are based on the animal model of the IBD. The models with rats or mice are widely used, nevertheless, they do not fully reflect the human disease. First of all, the occurrence of IBD is a result of the coexistence of many factors (internal and external as additional diseases, diets, genetic background), which cannot be fully reflected in the lab
Lactobacillus casei and Bifidobacterium lactis, can have beneficial effects in experimental Inflammatory Bowel Disease (IBD) models in mice, including reducing tissue damage of the intestinal mucosa and liver
The basic scientific literature has shown potentially useful physiological effects of probiotics in animal models of Inflammatory Bowel Disease (IBD).
Some conflicting results from clinical trials have been reported, highlighting the need for a better understanding of the specific bacterial strains or combinations that would be most effective in treating Inflammatory Bowel Disease (IBD)
According to the literature, probiotic bacteria can affect all aspects of Inflammatory Bowel Disease (IBD) pathoetiology, and can fulfil a protective function for the patient
Fujiya et al. (101) reviewed 20 randomized controlled trials in 1004 subjects who had active IBD (ulcerative colitis [UC] and Crohn’s disease), exploring the role of probiotics as a therapeutic modality
Oral treatment with specific bacteria can ameliorate IBD
There are few well-designed randomized clinical trials (RCTs) of probiotics in Inflammatory Bowel Disease (IBD). A variety of probiotics have been studied in various dosages and regimens, making a direct comparison of their efficacy impossible.
see also:
Aloe vera / Aloe vera (Barbadensis Miller) & Inflammatory Bowel Disease (IBD)
Dendritic Cells (DCs) & Toll-like receptors (TLRs)
Bifidobacterium / Bifidobacter & Inflammatory Bowel Disease (IBD)
Bifidobacterium / Bifidobacter + Lactobacillus acidophilus + Enterococcus & Inflammatory Bowel Disease (IBD)
Bifidobacterium longum & Inflammatory Bowel Disease (IBD)
Probiotics (living agents) & Crohn’s Disease (CD)
Probiotics (living agents) & Inflammatory Bowel Disease (IBD)
RBX2660 & Inflammatory Bowel Disease (IBD)
VE202 & Inflammatory Bowel Disease (IBD)
XXX - Bifidobacterium longum longum CCM 7952 vs Bifidobacterium longum longum CCDM 372 & Colitis / Intestinal Inflammation ( Dextran Sulfate Sodium induced (DSS))
XXX - Bifidobacterium longum BAA2573 & Colitis / Intestinal Inflammation (Dextran Sulfate Sodium induced (DSS))